Top

Published in:

01-12-2019 | Metastasis | Original Article

Identification of gene co-expression modules and hub genes associated with lymph node metastasis of papillary thyroid cancer

Authors: Tianyu Zhai, Dilidaer Muhanhali, Xi Jia, Zhiyong Wu, Zhenqin Cai, Yan Ling

Published in: Endocrine | Issue 3/2019

Abstract

Papillary thyroid cancer (PTC) is the most prevalent histological type among thyroid cancers, and some patients are at a high risk for recurrent disease or even death. Identification for the potential biomarkers of PTC may contribute to early discovery of recurrence and treatment. In The Cancer Genome Atlas (TCGA) database, we obtained the information of RNA sequence data and clinical characteristics of PTC. Weighted gene co-expression network analysis (WGCNA) was performed to construct gene co-expression networks and investigate the relationship between modules and clinical traits. Finally, we constructed 16 co-expression modules in 10,428 genes, and three key modules (darkturquoise, lightyellow, and red) associated with tumor N grade were identified. The results of functional annotation indicated that the darkturquoise module was primarily enriched in the regulation of the extracellular matrix (ECM), collagen metabolism, and cell adhesion, the lightyellow module was primarily enriched in the mitochondrial function regulation and energy synthesis, and the red module was primarily enriched in the process of cell junction, apoptosis, and inflammatory response, suggesting their significant role in the progression of PTC. In addition, the hub genes in the three modules were identified and screened for differentially expressed genes (DEGs). Relapse-free survival analyses found that 11 genes (KCNQ3, MET, FN1, ITGA3, RUNX1, ITGA2, PERP, GCSH, FAAH, NGFRAP1, and HSPA5) may play a pivotal role in PTC relapse. In general, our research revealed the key co-expression modules and identified several prognostic biomarkers, which provides some new insights into the lymph node metastasis of PTC.

Available only for authorised users

W. Chen, R. Zheng, T. Zuo, H. Zeng, S. Zhang, J. He, National cancer incidence and mortality in China, 2012. Chin. J. Cancer Res. 28(1), 1–11 (2016). https://doi.org/10.3978/j.issn.1000-9604.2016.02.08 CrossRefPubMedPubMedCentral

C.M. Kitahara, J.A. Sosa, The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 12(11), 646–653 (2016). https://doi.org/10.1038/nrendo.2016.110 CrossRefPubMed

Y. Wang, W. Wang, Increasing Incidence of Thyroid Cancer in Shanghai, China, 1983-2007. Asia Pac. J. Public Health 27(2), NP223–NP229 (2015). https://doi.org/10.1177/1010539512436874 CrossRefPubMed

D.S. McLeod, Current concepts and future directions in differentiated thyroid cancer. Clin. Biochem Rev. 31(1), 9–19 (2010)PubMedPubMedCentral

M.J. Schlumberger, Papillary and follicular thyroid carcinoma. N. Engl. J. Med 338(5), 297–306 (1998). https://doi.org/10.1056/nejm199801293380506 CrossRefPubMed

H. Li, Z. Tian, Y. Qu, Q. Yang, H. Guan, B. Shi, M. Ji, P. Hou, SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis. Oncogene 1–13 (2018). https://doi.org/10.1038/s41388-018-0434-6 CrossRef

X. Li, X. Ruan, P. Zhang, Y. Yu, M. Gao, S. Yuan, Z. Zhao, J. Yang, L. Zhao, TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57KIP2 repression. Oncogene 37(21), 2773–2792 (2018). https://doi.org/10.1038/s41388-017-0090-2 CrossRefPubMed

Y. Li, Q. Yang, H. Guan, B. Shi, M. Ji, P. Hou, ZNF677 suppresses Akt phosphorylation and tumorigenesis in thyroid cancer. Cancer Res. 5216–5228 (2018). https://doi.org/10.1158/0008-5472.can-18-0003 CrossRef

S. Ock, J. Ahn, S.H. Lee, H. M. Kim, H. Kang, Y.-K. Kim, Y.-K., H. Kook, W.J. Park, S. Kim, S. Kimura, C.K. Jung, M. Shong, M. Holzenberger, E. Dale Abel, T.J. Lee, B.Y. Cho, H.-S. Kim, J. Kim, Thyrocyte-specific deletion of insulin and IGF-1 receptors induces papillary thyroid carcinoma-like lesions through EGFR pathway activation. Int. J. Cancer 1–13 (2018). https://doi.org/10.1002/ijc.31779 CrossRef

10.

S. Tavazoie, J.D. Hughes, M.J. Campbell, R.J. Cho, G.M. Church, Systematic determination of genetic network architecture. Nat. Genet. 22(3), 281–285 (1999). https://doi.org/10.1038/10343 CrossRefPubMed

11.

A.P. Presson, E.M. Sobel, J.C. Papp, C.J. Suarez, T. Whistler, M.S. Rajeevan, S.D. Vernon, S. Horvath, Integrated weighted gene co-expression network analysis with an application to chronic fatigue syndrome. BMC Syst. Biol. 2, 95–116 (2008). https://doi.org/10.1186/1752-0509-2-95 CrossRefPubMedPubMedCentral

12.

P. Langfelder, S. Horvath, WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 9, 559–572 (2008). https://doi.org/10.1186/1471-2105-9-559 CrossRef

13.

M. Giulietti, G. Occhipinti, G. Principato, F. Piva, Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis. Cell. Oncol. 40(2), 181–192 (2017). https://doi.org/10.1007/s13402-017-0315-y CrossRef

14.

X. Shao, B. Wang, K. Mu, L. Li, Q. Li, W. He, Q. Yao, X. Jia, J.-a.Zhang, Key gene co-expression modules and functional pathways involved in the pathogenesis of Graves’ disease. Mol. Cell. Endocrinol. 474, 252–259 (2018). https://doi.org/10.1016/j.mce.2018.03.015 CrossRefPubMed

15.

N. Shved, G. Warsow, F. Eichinger, D. Hoogewijs, S. Brandt, P. Wild, M. Kretzler, C.D. Cohen, M.T. Lindenmeyer, Transcriptome-based network analysis reveals renal cell type-specific dysregulation of hypoxia-associated transcripts. Sci. Rep. 7(1), 8576–8593 (2017). https://doi.org/10.1038/s41598-017-08492-y CrossRefPubMedPubMedCentral

16.

G.J. Dennis, B.T. Sherman, D.A. Hosack, J. Yang, W. Gao, H.C. Lane, R.A. Lempicki, DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 4(5), P3–P14 (2003)CrossRef

17.

M. Ashburner, C.A. Ball, J.A. Blake, D. Botstein, H. Butler, J.M. Cherry, A.P. Davis, K. Dolinski, S.S. Dwight, J.T. Eppig, M.A. Harris, D.P. Hill, L. Issel-Tarver, A. Kasarskis, S. Lewis, J.C. Matese, J.E. Richardson, M. Ringwald, G.M. Rubin, G. Sherlock, Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat. Genet 25(1), 25–29 (2000). https://doi.org/10.1038/75556 CrossRefPubMedPubMedCentral

18.

M. Kanehisa, S. Goto, Y. Sato, M. Furumichi, M. Tanabe, KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 40(D1), D109–D114 (2011). https://doi.org/10.1093/nar/gkr988 CrossRefPubMedPubMedCentral

19.

C.V. Mering, STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 31(1), 258–261 (2003). https://doi.org/10.1093/nar/gkg034 CrossRef

20.

G. Alanis-Lobato, M.A. Andrade-Navarro, M.H. Schaefer, HIPPIE v2.0: enhancing meaningfulness and reliability of protein–protein interaction networks. Nucleic Acids Res. 45(D1), D408–D414 (2017). https://doi.org/10.1093/nar/gkw985 CrossRefPubMed

21.

P. Shannon, A. Markiel, O. Ozier, N.S. Baliga, J.T. Wang, D. Ramage, N. Amin, B. Schwikowski, T. Ideker, Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13(11), 2498–2504 (2003). https://doi.org/10.1101/gr.1239303 CrossRefPubMedPubMedCentral

22.

J.M. Wettenhall, G.K. Smyth, limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 20(18), 3705–3706 (2004). https://doi.org/10.1093/bioinformatics/bth449 CrossRefPubMed

23.

Y.E. Nikiforov, M.N. Nikiforova, Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrin. 7(10), 569–580 (2011). https://doi.org/10.1038/nrendo.2011.142 CrossRef

24.

V.A. LiVolsi, Papillary thyroid carcinoma: an update. Mod. Pathol. 24(Suppl 2), S1–S9 (2011). https://doi.org/10.1038/modpathol.2010.129 CrossRefPubMed

25.

K. Rue-Albrecht, P.A. McGettigan, B. Hernández, N.C. Nalpas, D.A. Magee, A.C. Parnell, S.V. Gordon, D.E. MacHugh, GOexpress: an R/Bioconductor package for the identification and visualisation of robust gene ontology signatures through supervised learning of gene expression data. BMC Bioinform. 17(1), 126–138 (2016). https://doi.org/10.1186/s12859-016-0971-3 CrossRef

26.

C. Puppin, D. Fabbro, M. Dima, C. Di Loreto, E. Puxeddu, S. Filetti, D. Russo, G. Damante, High periostin expression correlates with aggressiveness in papillary thyroid carcinomas. J. Endocrinol. 197(2), 401–408 (2008). https://doi.org/10.1677/joe-07-0618 CrossRefPubMed

27.

L.A. Jolly, S. Novitskiy, P. Owens, N. Massoll, N. Cheng, W. Fang, H.L. Moses, A.T. Franco, Fibroblast-mediated collagen remodeling within the tumor microenvironment facilitates progression of thyroid cancers driven by BrafV600E and Pten loss. Cancer Res. 76(7), 1804–1813 (2016). https://doi.org/10.1158/0008-5472.can-15-2351 CrossRefPubMedPubMedCentral

28.

P. Boffetta, M. Hashibe, C. La Vecchia, W. Zatonski, J. Rehm, The burden of cancer attributable to alcohol drinking. Int. J. Cancer 119(4), 884–887 (2006). https://doi.org/10.1002/ijc.21903 CrossRefPubMed

29.

S.-T. Tsai, T.-Y. Wong, C.-Y. Ou, S.-Y. Fang, K.-C. Chen, J.-R. Hsiao, C.-C. Huang, W.-T. Lee, H.-I. Lo, J.-S. Huang, J.-L. Wu, C.-J. Yen, W.-T. Hsueh, Y.-H. Wu, M.-W. Yang, F.-C. Lin, J.-Y. Chang, K.-Y. Chang, S.-Y. Wu, H.-C. Liao, C.-L. Lin, Y.-H. Wang, Y.-L. Weng, H.-C. Yang, J.S. Chang, The interplay between alcohol consumption, oral hygiene, ALDH2 and ADH1B in the risk of head and neck cancer. Int. J. Cancer 135(10), 2424–2436 (2014). https://doi.org/10.1002/ijc.28885 CrossRefPubMed

30.

I. Bieche, B. Franc, D. Vidaud, M. Vidaud, R. Lidereau, Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid 11(2), 147–152 (2001). https://doi.org/10.1089/105072501300042802 CrossRefPubMed

31.

G.-Y. Liu, Q. Luo, B. Xiong, C. Pan, P. Yin, H.-F. Liao, W.-C. Zhuang, H.-Z. Gao, Tissue array for Tp53, C-myc, CCND1 gene over-expression in different tumors. World J. Gastroenterol. 14(47), 7199–7207 (2008). https://doi.org/10.3748/wjg.14.7199 CrossRefPubMedPubMedCentral

32.

J. Sun, R. Shi, S. Zhao, X. Li, S. Lu, H. Bu, X. Ma, C. Su, E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle. J. Exp. Clin. Cancer Res. 36(1), 1–14 (2017). https://doi.org/10.1186/s13046-017-0504-6 CrossRef

33.

P.A. Siironen, Ivi, S. Nordling, J. Louhimo, R. Haapiainen, C. Haglund, Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer. Tumor Biol. 26(1), 50–56 (2005). https://doi.org/10.1159/000084340 CrossRef

34.

G.H. Xiao, M. Jeffers, A. Bellacosa, Y. Mitsuuchi, W.G. Vande, J.R. Testa, Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl Acad. Sci. USA 98(1), 247–252 (2001). https://doi.org/10.1073/pnas.011532898 CrossRefPubMed

35.

S. Fan, Y.X. Ma, J.A. Wang, R.Q. Yuan, Q. Meng, Y. Cao, J.J. Laterra, I.D. Goldberg, E.M. Rosen, The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3’ kinase. Oncogene 19(18), 2212–2223 (2000). https://doi.org/10.1038/sj.onc.1203566 CrossRefPubMed

36.

P.W. Derksen, D.J. de Gorter, H.P. Meijer, R.J. Bende, M. van Dijk, H.M. Lokhorst, A.C. Bloem, M. Spaargaren, S.T. Pals, The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17(4), 764–774 (2003). https://doi.org/10.1038/sj.leu.2402875 CrossRefPubMed

37.

S.-N. Jung, H.S. Lim, L. Liu, J.W. Chang, Y.C. Lim, K.S. Rha, B.S. Koo, LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals. Sci. Rep. 8(1), 2718–2728 (2018). https://doi.org/10.1038/s41598-018-21216-0 CrossRefPubMedPubMedCentral

38.

B.S. Koo, J.M. Kim, S.T. Seo, Y.H. Yoon, K.R. Kwon, S.H. Kim, H.W. Kwon, W.J. Bae, Y.C. Lim, Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Ann. Surg. Oncol. 21(7), 2310–2317 (2014). https://doi.org/10.1245/s10434-014-3553-5 CrossRefPubMed

39.

Y.-X. Liao, Z.-P. Zhang, J. Zhao, J.-P. Liu, Effects of fibronectin 1 on cell proliferation, senescence and apoptosis of human glioma cells through the PI3K/AKT signaling pathway. Cell. Physiol. Biochem. 48(3), 1382–1396 (2018). https://doi.org/10.1159/000492096 CrossRefPubMed

40.

B. Erdogan, M. Ao, L.M. White, A.L. Means, B.M. Brewer, L. Yang, M.K. Washington, C. Shi, O.E. Franco, A.M. Weaver, S.W. Hayward, D. Li, D.J. Webb, Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J. Cell Biol. 216(11), 3799–3816 (2017). https://doi.org/10.1083/jcb.201704053 CrossRefPubMedPubMedCentral

41.

J. Dong, R. Wang, G. Ren, X. Li, J. Wang, Y. Sun, J. Liang, Y. Nie, K. Wu, B. Feng, Y. Shang, D. Fan, HMGA2-FOXL2 axis regulates metastases and epithelial-to-mesenchymal transition of chemoresistant gastric cancer. Clin. Cancer Res. 23(13), 3461–3473 (2017). https://doi.org/10.1158/1078-0432.CCR-16-2180.CrossRefPubMed

42.

X.-R. Tang, X. Wen, Q.-M. He, Y.-Q. Li, X.-Y. Ren, X.-J. Yang, J. Zhang, Y.-Q. Wang, J. Ma, N. Liu, MicroRNA-101 inhibits invasion and angiogenesis through targeting ITGA3 and its systemic delivery inhibits lung metastasis in nasopharyngeal carcinoma. Cell Death Dis. 8(1), e2566–e2566 (2017). https://doi.org/10.1038/cddis.2016.486 CrossRefPubMedPubMedCentral

43.

T. Sakaguchi, H. Yoshino, M. Yonemori, K. Miyamoto, S. Sugita, R. Matsushita, T. Itesako, S. Tatarano, M. Nakagawa, H. Enokida, Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. Br. J. Cancer 116(8), 1077–1087 (2017). https://doi.org/10.1038/bjc.2017.43 CrossRefPubMedPubMedCentral

44.

G. Zhang, G. Han, X. Zhang, Q. Yu, Z. Li, Z. Li, J. Li, Long non-coding RNA FENDRR reduces prostate cancer malignancy by competitively binding miR-18a-5p with RUNX1. Biomarkers 23(5), 435–445 (2018). https://doi.org/10.1080/1354750x.2018.1443509 CrossRefPubMed

45.

Y. Mitsuda, K. Morita, G. Kashiwazaki, J. Taniguchi, T. Bando, M. Obara, M. Hirata, T.R. Kataoka, M. Muto, Y. Kaneda, T. Nakahata, P.P. Liu, S. Adachi, H. Sugiyama, Y. Kamikubo, RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. Sci. Rep. 8(1), 6423–6436 (2018). https://doi.org/10.1038/s41598-018-24969-w CrossRefPubMedPubMedCentral

46.

M. Kulkarni, T.Z. Tan, S.N. Syed, J.M. Lamar, P. Bansal, J. Cui, Y. Qiao, Y. Ito, RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer. Oncotarget 9(18), 14175–14192 (2018). https://doi.org/10.18632/oncotarget.24419 CrossRefPubMedPubMedCentral

47.

I.A. Khan, B.H. Yoo, O. Masson, S. Baron, D. Corkery, G. Dellaire, L.D. Attardi, K.V. Rosen, ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells. Oncogene 35(44), 5759–5769 (2016). https://doi.org/10.1038/onc.2016.109 CrossRef

48.

V.G. Beaudry, D. Jiang, R.L. Dusek, E.J. Park, S. Knezevich, K. Ridd, H. Vogel, B.C. Bastian, L.D. Attardi, Loss of the p53/p63 regulated desmosomal protein Perp promotes tumorigenesis. PLoS Genet. 6(10), e1001168–e1001185 (2010). https://doi.org/10.1371/journal.pgen.1001168 CrossRefPubMedPubMedCentral

49.

W. Gao, J.Z. Li, S.Q. Chen, C.Y. Chu, J.Y. Chan, T.S. Wong, BEX3 contributes to cisplatin chemoresistance in nasopharyngeal carcinoma. Cancer Med. 6(2), 439–451 (2017). https://doi.org/10.1002/cam4.982 CrossRefPubMedPubMedCentral

50.

S.Y. Kim, H.J. Kim, H.J. Kim, D.H. Kim, J.H. Han, H.K. Byeon, K. Lee, C.H. Kim, HSPA5 negatively regulates lysosomal activity through ubiquitination of MUL1 in head and neck cancer. Autophagy 14(3), 385–403 (2018). https://doi.org/10.1080/15548627.2017.1414126 CrossRefPubMedPubMedCentral

51.

H.A. Chen, Y.W. Chang, C.F. Tseng, C.F. Chiu, C.C. Hong, W. Wang, M.Y. Wang, M. Hsiao, J.T. Ma, C.H. Chen, S.S. Jiang, C.H. Wu, M.C. Hung, M.T. Huang, J.L. Su, E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer. Ann. Surg. Oncol. 22(3), 889–898 (2015). https://doi.org/10.1245/s10434-014-4061-3 CrossRefPubMed

52.

D. Fiore, M.C. Proto, S. Pisanti, P. Picardi, A.C. Pagano Zottola, S. Butini, S. Gemma, A. Casagni, C. Laezza, M. Vitale, A. Ligresti, V. Di Marzo, D.M. Zisterer, S. Nathwani, D.C. Williams, G. Campiani, P. Gazzerro, M. Bifulco, Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells. Cancer Biol. Ther. 17(8), 849–858 (2016). https://doi.org/10.1080/15384047.2015.1078028 CrossRefPubMed

53.

M.P. Endsley, R. Thill, I. Choudhry, C.L. Williams, A. Kajdacsy-Balla, W.B. Campbell, K. Nithipatikom, Expression and function of fatty acid amide hydrolase in prostate cancer. Int. J. Cancer 123(6), 1318–1326 (2008). https://doi.org/10.1002/ijc.23674 CrossRefPubMedPubMedCentral

54.

G. Chernaya, N. Mikhno, T. Khabalova, S. Svyatchenko, L. Mostovich, S. Shevchenko, L. Gulyaeva, The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation. Surg. Oncol. 27(4), 702–708 (2018). https://doi.org/10.1016/j.suronc.2018.09.007 CrossRefPubMed

Title: Identification of gene co-expression modules and hub genes associated with lymph node metastasis of papillary thyroid cancer
Authors: Tianyu Zhai
Dilidaer Muhanhali
Xi Jia
Zhiyong Wu
Zhenqin Cai
Yan Ling
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Metastasis
Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: Endocrine / Issue 3/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-02021-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

miR-762 modulates thyroxine-induced cardiomyocyte hypertrophy by inhibiting Beclin-1

Multidisciplinary team efforts improve the surgical outcomes of sellar region lesions during pregnancy

An unusual epididymal localization of Testicular Adrenal Rest Tumor in an adolescent with congenital adrenal hyperplasia

Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice

Body muscle-to-fat ratio gender-specific cut-off values for impaired insulin sensitivity in patients with treatment-naïve type 2 diabetes mellitus

Growth hormone therapy in children: predictive factors and short-term and long-term response criteria

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage